Glaucoma or ocular hypertension shouldn’t take away special moments.



Learn More

If you’ve been diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT),
learn how you could participate in this study of an investigational eye drop.
English brochure

When treating open-angle glaucoma (OAG) or ocular hypertension (OHT) 


Your doctor’s priority is to lower the pressure in your eyes to prevent damage to the optic nerve. Lowering this pressure, called intraocular pressure, is important because it can cause vision loss when it gets too high. While some medications can help delay the progression of OAG or OHT, there is a need to develop additional medications that can safely lower intraocular pressure, while being convenient to use. In this study, doctors are evaluating whether an investigational eye drop can lower intraocular pressure. They want to compare the safety and efficacy of the investigational eye drop to placebo, which looks like the investigational eye drop, but contains no active medication. In previous studies of a mostly non-Japanese population, the investigational eye drop has shown to be safe and efficacious. This study is being conducted to ensure that similar results are shown in people of Japanese ethnicity. The results of this study will provide more information about the investigational eye drop and whether it could one day be used to help treat OAG or OHT.


Who is eligible to participate in this study?


To pre-qualify for this study, you must:

• Be 18 years of age or older

• Be of Japanese ethnicity within the second generation (proven by birth certificate or family tree)

• Have been diagnosed with OAG or OHT in both eyes (OAG in one eye and OHT in the other eye is acceptable)

All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related travel may be provided.






What will happen during this study?


If you are eligible for this study, and you agree to participate, you will be randomly assigned (like the flip of a coin) to 1 of 3 study groups. Two groups will receive the investigational drug and one group will receive placebo. You have a 66.7% chance of receiving the investigational drug and a 33.3% chance of receiving placebo. To prevent any biased opinions about the study drugs (investigational or placebo) from a‘ecting the study results, you, the study doctor, and the study sta‘ will not know study group assignments. However, in the event of an emergency, this information can be provided. You will administer your study drug once every evening for 28 days. Your total study participation will last approximately 29 days, which includes up to 6 study clinic visits for tests and assessments.


What are the benefits and risks related to this study?


There is no guarantee you will receive any benefit from participating in this study. However, your participation may help others with OAG or OHT in the future. It is also possible you could experience a side effect while in this study. The study coordinator will review the full list of side effects with you before you join the study. Your health and safety will be monitored while you are in this study. The sponsor of this study was required to design a protocol, which explains all study procedures in detail. An independent review board responsible for participant safety reviewed this protocol and requires that it be followed exactly.



About Research Studies


Pharmaceutical companies use research studies like this one to learn more about investigational drugs before they are made available to the public. The results of this study will provide more information about the investigational eye drop being evaluated. By taking part in this study, you will be making an important contribution to OAG or OHT treatment research.


P: 614.430.3030  |  F: 614.430.8025  |  RESEARCH@OPTIMED.US.COM